{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:16:11Z","timestamp":1790396171178,"version":"4.1.0"},"reference-count":99,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,9,1]]},"abstract":"<jats:p> This account of the highlights of the eighth St Gallen (Switzerland) meeting in 2003 emphasizes new information that has emerged during the 2 years since the seventh meeting in 2001. This article should be read in conjunction with the report of that earlier meeting. Recommendations for patient care are so critically dependent on assessment of endocrine responsiveness that the importance of high-quality steroid hormone receptor determination and standardized quantitative reporting cannot be overemphasized. The International Consensus Panel modified the risk categories so that only endocrine receptor\u2013absent status was sufficient to reclassify an otherwise low-risk, node-negative disease into the category of average risk. Absence of steroid hormone receptors also was recognized as indicating endocrine nonresponsiveness. Some important areas highlighted at the recent meeting include: (1) recognition of the separate nature of endocrine-nonresponsive breast cancer\u2014both invasive cancers and ductal carcinoma-in-situ; (2) improved understanding of the mechanisms of acquired endocrine resistance, which offer exciting prospects for extending the impact of successful sequential endocrine therapies; (3) presentation of high-quality evidence indicating that chemotherapy and tamoxifen should be used sequentially rather than concurrently; (4) availability of a potential alternative to tamoxifen for treatment of postmenopausal women with endocrine-responsive disease; and (5) the promise of newly defined prognostic and predictive markers. <\/jats:p>","DOI":"10.1200\/jco.2003.04.576","type":"journal-article","created":{"date-parts":[[2003,7,8]],"date-time":"2003-07-08T00:22:28Z","timestamp":1057623748000},"page":"3357-3365","source":"Crossref","is-referenced-by-count":552,"title":["Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer"],"prefix":"10.1200","volume":"21","author":[{"given":"Aron","family":"Goldhirsch","sequence":"first","affiliation":[{"name":"From the International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano; Division of Gynecologic Oncology, Kantonsspital; Zentrum f\u00fcr Tumordiagnostik und Pr\u00e4vention, Silberturm, Grossacker, St Gallen, Switzerland; European Institute of Oncology, Milan, Italy; Department of Surgery, Emory University, Atlanta, GA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; and The Cancer Council Australia, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Wood","sequence":"additional","affiliation":[{"name":"From the International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano; Division of Gynecologic Oncology, Kantonsspital; Zentrum f\u00fcr Tumordiagnostik und Pr\u00e4vention, Silberturm, Grossacker, St Gallen, Switzerland; European Institute of Oncology, Milan, Italy; Department of Surgery, Emory University, Atlanta, GA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; and The Cancer Council Australia, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[{"name":"From the International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano; Division of Gynecologic Oncology, Kantonsspital; Zentrum f\u00fcr Tumordiagnostik und Pr\u00e4vention, Silberturm, Grossacker, St Gallen, Switzerland; European Institute of Oncology, Milan, Italy; Department of Surgery, Emory University, Atlanta, GA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; and The Cancer Council Australia, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Coates","sequence":"additional","affiliation":[{"name":"From the International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano; Division of Gynecologic Oncology, Kantonsspital; Zentrum f\u00fcr Tumordiagnostik und Pr\u00e4vention, Silberturm, Grossacker, St Gallen, Switzerland; European Institute of Oncology, Milan, Italy; Department of Surgery, Emory University, Atlanta, GA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; and The Cancer Council Australia, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[{"name":"From the International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano; Division of Gynecologic Oncology, Kantonsspital; Zentrum f\u00fcr Tumordiagnostik und Pr\u00e4vention, Silberturm, Grossacker, St Gallen, Switzerland; European Institute of Oncology, Milan, Italy; Department of Surgery, Emory University, Atlanta, GA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; and The Cancer Council Australia, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00f6rg","family":"Senn","sequence":"additional","affiliation":[{"name":"From the International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Lugano; Division of Gynecologic Oncology, Kantonsspital; Zentrum f\u00fcr Tumordiagnostik und Pr\u00e4vention, Silberturm, Grossacker, St Gallen, Switzerland; European Institute of Oncology, Milan, Italy; Department of Surgery, Emory University, Atlanta, GA; Department of Biostatistical Science, Dana-Farber Cancer Institute, Boston, MA; and The Cancer Council Australia, Sydney, New South Wales, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3817"},{"key":"R2","unstructured":"Harbeck N, Kates RE, Look MP, et al: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res 62:4617,2002\u20134622,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.2.116"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1038\/35021093"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/nm0102-13"},{"key":"R6","unstructured":"Bartelink H, Begg AC, Martin JC, et al: Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am 6:2,2000\u201310,"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021967"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021153"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1038\/nm0203-152"},{"key":"R10","unstructured":"Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a, 2002 (abstr 143)"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Albain KS: Adjuvant chemo-endocrine therapy for breast cancer: Combined or sequential? Breast 12:S13,2003,  (suppl 1, abstr S36)","DOI":"10.1016\/S0960-9776(03)80036-X"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.14.1054"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Coates AS, Gelber RD, Goldhirsch A: Subsets within the chemotherapy overview: International Breast Cancer Study Group. Lancet 352:1783,1998\u20131784,","DOI":"10.1016\/S0140-6736(05)79861-5"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00842-2"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02292-3"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003459"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03301-7"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05483-6"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.5.353"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.24.1991"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12342-2"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.2.160"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203968"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2002.1279"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012158"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Cuzick J, Forbes J, Howell A: Tamoxifen for breast-cancer prevention. Lancet 361:178,2003,","DOI":"10.1016\/S0140-6736(03)12212-X"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.5.338"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3808"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.133"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Bryant J, Land S, Allred C, et al: DCIS: NSABP evidence from randomized trials. Breast 12:S9,2003,  (suppl 1, abstr S24)","DOI":"10.1016\/S0960-9776(03)80024-3"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020989"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020128"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Galimberti V: Evaluation of regional lymphnodes: New standards? Breast 12:S5,2003,  (suppl 1, abstr S9)","DOI":"10.1016\/S0960-9776(03)80009-7"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200107000-00012"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010874"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(02)00136-6"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.918"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Pierce LJ: Treatment guidelines and techniques in delivery of postmastectomy radiotherapy in management of operable breast cancer. J Natl Cancer Inst Monogr 30:117,2001\u2013124,","DOI":"10.1093\/oxfordjournals.jncimonographs.a003448"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.137.6.737"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)04277-3"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1053\/srao.2002.28662"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.4.259"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Hayes DF: Markers of increased risk for failure of adjuvant therapies. Breast 12:S14,2003,  (suppl 1, abstr S37)","DOI":"10.1016\/S0960-9776(03)80037-1"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Viale G: Histopathology of primary breast cancer 2003. Breast 12:S4,2003,  (suppl 1, abstr S8)","DOI":"10.1016\/S0960-9776(03)80008-5"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200002243420801"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Piccart MJ: New data on chemotherapy in the adjuvant setting. Breast 12:S4,2003,  (suppl 1, abstr S5)","DOI":"10.1016\/S0960-9776(03)80005-X"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Colleoni M: Preoperative systemic treatment: Prediction of responsiveness. Breast 12:S13,2003,  (suppl 1, abstr S35)","DOI":"10.1016\/S0960-9776(03)80035-8"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.21.4141"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09088-8"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.020"},{"key":"R54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.112"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.042"},{"key":"R56","doi-asserted-by":"crossref","unstructured":"Davidson NE: Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 30:67,2001\u201371,","DOI":"10.1093\/oxfordjournals.jncimonographs.a003464"},{"key":"R57","unstructured":"Castiglione-Gertsch M, O\u2019Neill A, Gelber RD, et al: Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre\/perimenopausal breast cancer patients (pts) who receive goserelin? First results of IBCSG trial VIII. Proc Am Soc Clin Oncol 21:38a,2002,  (abstr 149)"},{"key":"R58","doi-asserted-by":"crossref","unstructured":"Castiglione-Gertsch M: Chemo-endocrine therapy: Any need to combine? Breast 12:S11,2003,  (suppl 1, abstr S30)","DOI":"10.1016\/S0960-9776(03)80030-9"},{"key":"R59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.9.1483"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2651"},{"key":"R61","unstructured":"Hutchins L, Green S, Ravdin P, et al: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of Intergroup trial INT 0102. Proc Am Soc Clin Oncol 17:1a,1998,  (abstr 2)"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02841-5"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008236502420"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(01)00452-1"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.063"},{"key":"R67","unstructured":"Nabholtz J-M, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a,2002,  (abstr 141)"},{"key":"R68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.081"},{"key":"R69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.148"},{"key":"R70","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600334"},{"key":"R71","unstructured":"Pico C, Martin M, Jara C, et al: Epirubicin-cyclophosphamide (EC) chemotherapy plus tamoxifen (T) administered concurrent (Con) versus sequential (Sec): Randomized phase III trial in postmenopausal node-positive breast cancer (BC) patients\u2014GEICAM 9401 study. Proc Am Soc Clin Oncol 21:37a,2002,  (abstr 144)"},{"key":"R72","unstructured":"Sertoli MR, Pronzato P, Venturini M, et al: A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer. Proc Am Soc Clin Oncol 21:46a,2002,  (abstr 182)"},{"key":"R73","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003453"},{"key":"R74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"R75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.584"},{"key":"R76","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008334404825"},{"key":"R77","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801215)46:12+<2859::AID-CNCR2820461425>3.0.CO;2-U"},{"key":"R78","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"R79","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09962-2"},{"key":"R80","doi-asserted-by":"publisher","DOI":"10.1007\/BF01855122"},{"key":"R81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.6.710"},{"key":"R82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1385"},{"key":"R83","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.14.1041"},{"key":"R84","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9776(16)30022-4"},{"key":"R85","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.026"},{"key":"R86","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.515"},{"key":"R87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1380"},{"key":"R88","doi-asserted-by":"crossref","unstructured":"Langer AS: Side effects, quality-of-life issues, and trade-offs: The patient perspective. J Natl Cancer Inst Monogr 30:125,2001\u2013129,","DOI":"10.1093\/oxfordjournals.jncimonographs.a003449"},{"key":"R91","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(02)00877-X"},{"key":"R92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.6.1676"},{"key":"R93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.980"},{"key":"R94","doi-asserted-by":"crossref","unstructured":"Levine M, Whelan T: Decision-making process: Communicating risk\/benefits\u2014Is there an ideal technique? J Natl Cancer Inst Monogr 30:143,2001\u2013145,","DOI":"10.1093\/oxfordjournals.jncimonographs.a003452"},{"key":"R95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.5.1474"},{"key":"R96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198608283150906"},{"key":"R97","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<97::AID-CNCR16>3.0.CO;2-3"},{"key":"R98","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7233.474"},{"key":"R99","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf039"},{"key":"R100","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-6-547"},{"key":"R101","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.169"},{"key":"R102","doi-asserted-by":"crossref","unstructured":"Morrow M, Krontiras H: Who should not receive chemotherapy? Data from American databases and trials. J Natl Cancer Inst Monogr 30:109,2001\u2013113,","DOI":"10.1093\/oxfordjournals.jncimonographs.a003446"},{"key":"R103","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)05023-4"},{"key":"R104","doi-asserted-by":"crossref","unstructured":"Bartelink H: Radiotherapy to the conserved breast, chest wall, and regional nodes: Is there a standard? Breast 12:S9,2003,  (suppl 1, abstr S24)","DOI":"10.1016\/S0960-9776(03)80026-7"},{"key":"R105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3554"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.04.576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:29:59Z","timestamp":1653510599000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.04.576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,1]]},"references-count":99,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2003,9,1]]}},"alternative-id":["10.1200\/JCO.2003.04.576"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.04.576","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,1]]}}}